PT-179

Overview

PT-179 is an orthogonal Thalidomide ( HY-14658 ) derivative that targets cereblon without causing off-target degradation effects. PT-179 is able to specifically bind CRBN, form a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediate the degradation of the tagged protein. For example, PT-179 binds to the ubiquitin ligase substrate receptor cereblon by forming a complex with SD40 and efficiently degrades proteins N- or C-terminally fused to SD40 or SD36 (DC50 for eGFP: 4.5 nM and 14.3 nM). PT-179 can be used to develop compact protein degradation tagging platforms.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Ligands for E3 Ligase | Products > Signaling Pathways > Molecular Glues

Product Information

• Catalog No.: HY-160695
• CAS No.: 2924858-25-1
• Molecular Formula: C17H17N3O5
• Molecular Weight: 343.33
• Purity: 99.78%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution
• Availability: In-stock

Source

Original product source